Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Kyowa Hakko Kirin Pharma, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| KRN23 | Experimental | Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| KRN23 | Drug | Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor. |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Efficacy of Repeated SC Injections of KRN23. | Safety and efficacy of repeated SC injections of KRN23, from Baseline, as assessed by serum phosphorus levels, immunogenicity, adverse events and clinically significant changes in vital signs and laboratory testing. | 13.5 months,(50 visits) |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of Effect of Repeated SC Injections of KRN23 | Effect of repeated SC injections of KRN23, from baseline, on pharmacodynamic parameters (serum phosphorus) | 13.5 months, (50 visits) |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of Effect of Repeated SC Injections of KRN23 in Bone Substudy | Evaluation of effect of repeated SC injections of KRN23, compared to Placebo on bone mineral density, bone quality and histomorphometric parameters. | 13.5 months,(50 visits) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Amy Zhang, PhD | Kyowa Hakko Kirin Pharma, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94143 | United States | ||
| Yale University School of Medicine |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25919461 | Derived | Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015 Jul;100(7):2565-73. doi: 10.1210/jc.2015-1551. Epub 2015 Apr 28. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | KRN23 | Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses) KRN23: Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor. |
| FG001 | Bone Substudy KRN23 | A Bone substudy in eligible subjects will evaluate the effects of KRN23 on various bone parameters. Subjects will undergo clinical assessments, inclusive of DXA and pQCT at Visits 17 and 33 (prior to dosing), and the end-of-study visit, Visit 49. A subset of subjects will have a bone biopsy of the iliac crest at Visit 33. |
| FG002 | Bone Substudy Placebo | A Bone substudy in eligible subjects will evaluate the effects of KRN23 on various bone parameters. Subjects will undergo clinical assessments, inclusive of DXA and pQCT at Visits 17 and 33 (prior to dosing), and the end-of-study visit, Visit 49. A subset of subjects will have a bone biopsy of the iliac crest at Visit 33. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | KRN23 | Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses) KRN23: Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Safety and Efficacy of Repeated SC Injections of KRN23. | Safety and efficacy of repeated SC injections of KRN23, from Baseline, as assessed by serum phosphorus levels, immunogenicity, adverse events and clinically significant changes in vital signs and laboratory testing. | Posted | Count of Participants | Participants | 13.5 months,(50 visits) |
|
After the first dose of study drug in study through the end of study, up to 13.5 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | KRN23 | Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses) KRN23: Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cervical Spinal Stenosis | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| BRADYCARDIA | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
Due to the lack of enrollment, the bone substudy was terminated early.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Kyowa Kirin Pharmaceutical Development | Kyowa Kirin Pharmaceutical Development | 609-919-1100 | kkd.clintrial.82@kyowakirin.com |
Not provided
| ID | Term |
|---|---|
| D053098 | Familial Hypophosphatemic Rickets |
| ID | Term |
|---|---|
| D063730 | Rickets, Hypophosphatemic |
| D012279 | Rickets |
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000601956 | burosumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| New Haven |
| Connecticut |
| 06520 |
| United States |
| Clinical Research Center, Indiana University School of Medicine | Indianapolis | Indiana | 46202 | United States |
| Duke Clinical Research Unit | Durham | North Carolina | 27710 | United States |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | United States |
| Shriners Hospital for Children - Canada | Montreal | Quebec | H3G 1A6 | Canada |
| Related Info | View source |
| Bone Substudy KRN23 |
| BG002 | Bone Substudy Placebo |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | Bone Substudy Placebo |
|
|
| Secondary | Evaluation of Effect of Repeated SC Injections of KRN23 | Effect of repeated SC injections of KRN23, from baseline, on pharmacodynamic parameters (serum phosphorus) | Efficacy analysis set: All subjects who received at least 1 dose of KRN23 and completed at least one 28-day post-dose evaluation. | Posted | Mean | Full Range | mg/dL | 13.5 months, (50 visits) |
|
|
|
| Other Pre-specified | Evaluation of Effect of Repeated SC Injections of KRN23 in Bone Substudy | Evaluation of effect of repeated SC injections of KRN23, compared to Placebo on bone mineral density, bone quality and histomorphometric parameters. | Posted | Number | units on a scale | 13.5 months,(50 visits) |
|
|
|
| 0 |
| 21 |
| 3 |
| 21 |
| 21 |
| 21 |
| EG001 | Bone Substudy KRN23 | 0 | 1 | 0 | 1 | 1 | 1 |
| EG002 | Bone Substudy Placebo | 0 | 1 | 0 | 1 | 1 | 1 |
| Breast Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | CTCAE (4.0) | Systematic Assessment |
|
| Hypertensive crisis | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
| PALPITATIONS | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
|
| EAR PAIN | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| VERTIGO | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| DEAFNESS | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| HYPOACUSIS | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| DRY EYE | Eye disorders | CTCAE (4.0) | Systematic Assessment |
|
| EYE PRURITUS | Eye disorders | CTCAE (4.0) | Systematic Assessment |
|
| VOMITING | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| GINGIVAL ULCERATION | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| GASTROOESOPHAGEAL REFLUX DISEASE | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| TOOTHACHE | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| ABDOMINAL PAIN UPPER | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| LIP ULCERATION | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| NAUSEA | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| POOR DENTAL CONDITION | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| ABDOMINAL PAIN | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| LIP BLISTER | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| FOOD POISONING | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| ABDOMINAL DISCOMFORT | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| DIARRHOEA | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| IRRITABLE BOWEL SYNDROME | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| HAEMATOCHEZIA | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| INJECTION SITE HAEMATOMA | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| INFLUENZA LIKE ILLNESS | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| INJECTION SITE ERYTHEMA | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| FATIGUE | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| INJECTION SITE PAIN | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| GRAVITATIONAL OEDEMA | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| HYPOTHERMIA | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| APPLICATION SITE REACTION | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| PAIN | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| NODULE | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| INJECTION SITE REACTION | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| INJECTION SITE RASH | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| INJECTION SITE PRURITUS | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| HEPATIC STEATOSIS | Hepatobiliary disorders | CTCAE (4.0) | Systematic Assessment |
|
| SEASONAL ALLERGY | Immune system disorders | CTCAE (4.0) | Systematic Assessment |
|
| VULVOVAGINAL MYCOTIC INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| VIRAL PHARYNGITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| VIRAL INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| URINARY TRACT INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| TOOTH INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| SINUSITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| RESPIRATORY TRACT INFECTION VIRAL | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| POST PROCEDURAL INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| TOOTH ABSCESS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| VAGINITIS BACTERIAL | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| PHARYNGITIS STREPTOCOCCAL | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| PHARYNGITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| NASOPHARYNGITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| LARYNGITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| INFLUENZA | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| EAR INFECTION | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| GASTROENTERITIS VIRAL | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| BRONCHITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| GASTROENTERITIS | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| MUSCLE STRAIN | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| HEAD INJURY | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| GINGIVAL INJURY | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| EXCORIATION | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| CONTUSION | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| TOOTH FRACTURE | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| SOFT TISSUE INJURY | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| PROCEDURAL PAIN | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| POST PROCEDURAL SWELLING | Injury, poisoning and procedural complications | CTCAE (4.0) | Systematic Assessment |
|
| WHITE BLOOD CELL COUNT DECREASED | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| NEUTROPHIL COUNT DECREASED | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| BLOOD PRESSURE DECREASED | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| BLOOD CREATINE PHOSPHOKINASE INCREASED | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| ASPARTATE AMINOTRANSFERASE INCREASED | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| ALANINE AMINOTRANSFERASE INCREASED | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| TENDONITIS | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| MUSCULOSKELETAL PAIN | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| MUSCULOSKELETAL DISCOMFORT | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| MUSCLE SPASMS | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| JOINT SWELLING | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| JOINT EFFUSION | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| JOINT CREPITATION | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| HAEMARTHROSIS | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| CERVICAL SPINAL STENOSIS | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| BACK PAIN | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| ARTHRALGIA | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| SYNCOPE | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| SINUS HEADACHE | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| SCIATICA | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| RESTLESS LEGS SYNDROME | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| PARAESTHESIA | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| NEURITIS | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| MIGRAINE | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| HYPOAESTHESIA | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| HEADACHE | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| DYSKINESIA | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| DIZZINESS | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| CARPAL TUNNEL SYNDROME | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| BURNING SENSATION | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| INSOMNIA | Psychiatric disorders | CTCAE (4.0) | Systematic Assessment |
|
| DEPRESSION | Psychiatric disorders | CTCAE (4.0) | Systematic Assessment |
|
| RENAL PAIN | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| POLLAKIURIA | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| NEPHROLITHIASIS | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| HYPERCALCIURIA | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| HAEMATURIA | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| DYSURIA | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| DYSMENORRHOEA | Reproductive system and breast disorders | CTCAE (4.0) | Systematic Assessment |
|
| TONSILLAR HYPERTROPHY | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| SINUS CONGESTION | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| RESPIRATORY TRACT CONGESTION | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| OROPHARYNGEAL PAIN | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| NASAL CONGESTION | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| COUGH | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| ASTHMA | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| ALLERGIC RESPIRATORY SYMPTOM | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| SKIN REACTION | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| RASH | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| DERMATITIS CONTACT | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| DERMATITIS ALLERGIC | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| VARICOSE VEIN | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
| HOT FLUSH | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
Not provided
| D009140 |
| Musculoskeletal Diseases |
| D007015 | Hypophosphatemia, Familial |
| D015499 | Renal Tubular Transport, Inborn Errors |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D008664 | Metal Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D002128 | Calcium Metabolism Disorders |
| D017674 | Hypophosphatemia |
| D010760 | Phosphorus Metabolism Disorders |
| D014808 | Vitamin D Deficiency |
| D001361 | Avitaminosis |
| D003677 | Deficiency Diseases |
| D044342 | Malnutrition |
| D009748 | Nutrition Disorders |
|
| Ext Visit 2 /7 |
|
|
| Ext Visit 3 /14 |
|
|
| Ext Visit 4 /25 |
|
|
| Ext Visit 5 /0 |
|
|
| Ext Visit 6 /7 |
|
|
| Ext Visit 7 /14 |
|
|
| Ext Visit 8 /25 |
|
|
| Ext Visit 9 /0 |
|
|
| Ext Visit 10 /7 |
|
|
| Ext Visit 11 /14 |
|
|
| Ext Visit 12 /25 |
|
|
| Ext Visit 13 /0 |
|
|
| Ext Visit 14 /7 |
|
|
| Ext Visit 15 /14 |
|
|
| Ext Visit 16 /25 |
|
|
| Ext Visit 17 /0 |
|
|
| Ext Visit 18 /7 |
|
|
| Ext Visit 19 /14 |
|
|
| Ext Visit 20 /25 |
|
|
| Ext Visit 21 /0 |
|
|
| Ext Visit 22 /7 |
|
|
| Ext Visit 23 /14 |
|
|
| Ext Visit 24 /25 |
|
|
| Ext Visit 25 /0 |
|
|
| Ext Visit 26 /7 |
|
|
| Ext Visit 27 /14 |
|
|
| Ext Visit 28 /25 |
|
|
| Ext Visit 29 /0 |
|
|
| Ext Visit 30 /7 |
|
|
| Ext Visit 31 /14 |
|
|
| Ext Visit 32 /25 |
|
|
| Ext Visit 33 /0 |
|
|
| Ext Visit 34 /7 |
|
|
| Ext Visit 35 /14 |
|
|
| Ext Visit 36 /25 |
|
|
| Ext Visit 37 /0 |
|
|
| Ext Visit 38 /7 |
|
|
| Ext Visit 39 /14 |
|
|
| Ext Visit 40 /25 |
|
|
| Ext Visit 41 /0 |
|
|
| Ext Visit 42 /7 |
|
|
| Ext Visit 43 /14 |
|
|
| Ext Visit 44 /25 |
|
|
| Ext Visit 45 /0 |
|
|
| Ext Visit 46 /7 |
|
|
| Ext Visit 47 /14 |
|
|
| Ext Visit 48 /25 |
|
|
| Ext Visit 49 /38 |
|
|
| Ext Visit 50 /81 |
|
|